(CDAX, Health Care)



D		Value Indicators:	EUR	Share data:		Description:	
Buy		DCF:	4.07	Bloomberg:	AAQ GR	Producer of implants and	
	· ·	SotP:	4.38	Reuters:	AAQG.DE	biomaterials to mend broker	bones
EUR 4.00	(EUR 4.50)	Peer Group:	4.62	ISIN:	DE0005066609		
		Market Snapshot:	EUR m	Shareholders:		Risk Profile (WRe):	2014e
		Market cap:	67.5	Freefloat	29.2 %	Beta:	1.4
Price	EUR 2.20	No. of shares (m):	30.7	Noes de Vries	14.7 %	Price / Book:	1.4 x
Upside	81.8 %	EV:	48.4	Elocin B.V	14.4 %	Equity Ratio:	81 %
		Freefloat MC:	19.7	Jürgen W. Krebs	12.6 %		
		Ø Trad. Vol. (30d; EUR):	103.35 th	Fidelity Funds	5.5 %		

Changed estimates after reduced guidance; new PT

aap Implante AG reduced its guidance for the current fiscal year. Hence, we updated our model, taking the published forecast into account.

New guidance: Sales EUR 30-34m and EUR 2-4.5m for EBITDA.

Old guidance (adjusted for consolidation effects): Sales EUR 34m and EUR 5-6m for EBITDA.

Despite the reduced forecast for the remainder of the fiscal year, we see the company as still on track to achieve its target of becoming a pure player in the Trauma market. The potentially negative effects mentioned in the box below are mainly related to the delayed roll-out of LOQTEQ products in North and South America. Hence, it is worth mentioning that these effects only pose a potential shift of orders into the next fiscal year and not a cancellation of orders. In our point of view, the duration of approval processes (Brazil and Mexico) as well as the decision-making processes at distribution partners in the US were underestimated by aap's management. Hence, the timing of the so far estimated orders, which have led now to the guidance reduction, is out of reach for aap.

Other current projects at the company are still running well and are not expected to be negatively affected by the recent newsflow. This relates to the divestment of Biomaterials business as well as the general expansion of the Trauma business. Within the last update we already mentioned the strong development of the Biomaterials business in the first nine months, which could lead the company to reach the upper end of an anticipated proceed range of EUR 36-40m (WRe). Further newsflow is expected within the upcoming weeks.


The next reporting date will be November 14, when aap releases its full 2014 Q3 figures. As preliminary sales figures were already reported, surprises should be limited. Q3 sales came in at EUR 7.6m which corresponds with EUR 22.8m for the first nine months. EBITDA is expected to be reported at EUR 0.6m (WRe) for Q3, which leads to an EBITDA of EUR 2.2m (WRe) for 9M.

The Buy rating is reiterated with a new price target of EUR 4.00 based on DCF.

Changes in E	stimates:						Comment on Changes:
FY End: 31.12. in EUR m	2014e (old)	+/-	2015e (old)	+ / -	2016e (old)	+/-	LOQTEQ in Latin America and the potential postponement of the market
Sales EBITDA EBT EPS	34.6 5.3 2.9 0.09	-11.6 % -46.6 % -86.3 % -88.9 %	40.3 6.7 3.9 0.12	-6.2 % -23.0 % -35.2 % -33.3 %	47.1 7.9 4.7 0.13	-2.8 % -17.2 % -27.0 % -30.8 %	 entry in the US. Additionally, potential delays of projects regarding the silver coating technology are reflected in the reduced forecast. EBITDA and EBIT are reduced disproportionally. With EUR 15m in sales the Trauma segment was expected to come in at break-even. Now, the black zero is assumed in 2015e.

3.25 h. h.		FY End: 31.12. in EUR m	CAGR (13-16e)	2010	2011	2012	2013	2014e	2015e	2016e
s. N Ph 2 W 1/ M		Sales	4.7 %	28.4	29.2	36.4	40.0	30.6	37.8	45.8
2.76 -	I M	Change Sales yoy		-14.1 %	2.7 %	24.7 %	9.8 %	-23.6 %	23.9 %	21.1 %
	W Walth	Gross profit margin		81.0 %	85.3 %	78.4 %	72.7 %	71.0 %	73.0 %	73.5 %
25-	AAK.	EBITDA	-3.8 %	3.4	4.1	7.1	7.4	2.8	5.2	6.6
2.25 A N	1.11	Margin		12.1 %	14.1 %	19.6 %	18.4 %	9.3 %	13.7 %	14.3 %
2-11-1-1		EBIT	-	0.7	1.2	3.2	-2.1	0.2	2.4	3.3
1.75 -		Margin		2.5 %	4.0 %	8.8 %	-5.3 %	0.8 %	6.4 %	7.3 %
16	$\sim \sim \sim \sim$	Net income	-	0.0	0.4	2.4	-2.5	0.2	2.3	2.8
01/14 03/14 06/14 07/14	09/14 11/14	EPS	-	0.00	0.01	0.08	-0.08	0.01	0.08	0.09
epine astro astro otte		DPS	-	0.00	0.00	0.00	0.00	0.00	0.02	0.03
— sap impanane — Cons (norma	insea)	Dividend Yield		0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.9 %	1.4 %
Rel. Performance vs CDAX	K:	FCFPS		-0.06	-0.03	0.10	-0.11	0.14	0.02	0.05
1 month:	-10.9 %	EV / Sales		1.5 x	1.2 x	0.9 x	1.2 x	1.6 x	1.3 x	1.0 x
6 months:	-27.6 %	EV / EBITDA		12.8 x	8.7 x	4.8 x	6.6 x	17.0 x	9.1 x	6.9 x
		EV / EBIT		61.3 x	30.8 x	10.7 x	n.a.	198.1 x	19.5 x	13.4 x
Year to date:	4.6 %	P/E		n.a.	96.9 x	12.5 x	n.a.	220.0 x	27.5 x	24.4 x
Trailing 12 months:	40.4 %	FCF Yield Potential		7.5 %	2.6 %	11.0 %	8.6 %	0.1 %	4.7 %	6.1 %
Commons overter		Net Debt		9.1	7.1	3.9	3.3	-19.1	-20.2	-22.5
Company events:		ROE		0.1 %	0.8 %	4.9 %	-4.9 %	0.4 %	4.6 %	5.3 %
14.11.14	Q3	ROCE (NOPAT)		0.4 %	1.4 %	5.2 %	-4.3 %	0.3 %	7.3 %	8.6 %
		Guidance:	Guidance 201	4: Revenue E	EUR 30-34m	- EBITDA EL	JR 2-4.5m			






Company Background

- aap Implantate AG develops, produces and sells medical implants, which are primarily used in orthopaedics to mend fractures.
- With the business areas Trauma and Biomaterials, the company covers the entire value chain and sells the products worldwide with the focus on Europe, the USA as well as on the BRICS and SMIT markets.
- The products are sold by direct sale, international sales partners or OEMs (including Stryker, Zimmer, Biomet or Smith& Nephew).
- aap Implantate AG was founded in 1990 as a MBO from the Johnson & Johnson Group and is headquartered in Berlin. The company has 217 employees.

Competitive Quality

- aap Implantate AG has developed a patent protected Trauma implant (LOQTEQ), which provides significant improvements for surgeons, hospitals and clinics as well as patients.
- Additionally aap has a promising product pipeline with an antibacterial silver coating for the implants as well as resorbable magnesium implants.
- The most recent sale of the Dutch subsidiary has provided the company with sufficient financial funds to grow organically and inorganically.
- In the Biomaterials division, aap has established a network with the largest Medtech companies (e.g. Zimmer, Stryker, Smith &Nephew, Johnson & Johnson).





DCF model														
	Detaile	d forecas	t period				٦	ransition	al period					Term. Value
Figures in EUR m	2014e	2015e	2016e	2017e	2018e	2019e	2020e	2021e	2022e	2023e	2024e	2025e	2026e	
Sales	30.6	37.8	45.8	53.9	59.7	65.3	70.0	74.8	79.6	84.4	89.6	94.8	100.0	
Sales change	-23.6 %	23.9 %	21.1 %	17.6 %	10.6 %	9.5 %	7.1 %	6.8 %	6.4 %	6.1 %	6.1 %	5.8 %	5.5 %	3.5 %
EBIT	0.2	2.4	3.3	4.7	5.9	7.1	8.2	10.1	12.2	14.5	17.0	19.4	20.5	
EBIT-margin	0.8 %	6.4 %	7.3 %	8.8 %	9.9 %	10.8 %	11.7 %	13.5 %	15.3 %	17.2 %	19.0 %	20.5 %	20.5 %	
Tax rate (EBT)	50.7 %	7.9 %	17.4 %	17.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	25.0 %	
NOPAT	0.1	2.2	2.8	3.9	4.4	5.3	6.1	7.6	9.1	10.9	12.8	14.6	15.4	
Depreciation	2.6	2.8	3.2	3.5	3.9	4.2	4.5	4.9	5.2	5.5	5.8	6.2	6.5	
in % of Sales	8.5 %	7.3 %	7.0 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	
Changes in provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Change in Liquidity from														
- Working Capital	-4.8	1.3	1.2	1.7	1.4	1.4	0.8	1.1	1.1	1.1	1.2	0.7	1.2	
- Capex	3.2	3.3	3.4	3.5	3.9	4.2	4.5	4.9	5.2	5.5	5.8	6.2	6.5	
Capex in % of Sales	10.5 %	8.7 %	7.4 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	6.5 %	
Other	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	
Free Cash Flow (WACC Model)	4.3	0.4	1.4	2.3	3.1	3.9	5.4	6.4	8.0	9.8	11.6	13.8	14.2	16
PV of FCF	4.2	0.3	1.1	1.7	2.0	2.4	3.0	3.2	3.6	4.0	4.3	4.7	4.4	73
share of PVs		5.07 %						29.7	6 %					65.17 %
Model parameter							Valuat	ion (m)						
Derivation of WACC:			Derivation	of Beta:			Presen	t values 20	026e	3	9			
							Termin	al Value		7	'3			
Debt ratio	0.00 %		Financial S	0		1.20	Financi	al liabilitie	S		4			
Cost of debt (after tax)	4.2 %		Liquidity (s	hare)		1.50	Pensio	n liabilities			0			
Market return	8.00 %		Cyclicality			1.40	Hybrid				0			
Risk free rate	2.50 %		Transpare	ncy		1.40		y interest			0			
			Others			1.38	Market	val. of inv	estments		0			
							Liquidit	,				No. of sha	. ,	30.7
WACC	10.06 %		Beta			1.38	Equity	Value		12	25	Value per	share (E	UR) 4.07

Sensitivity Value per Share (EUR)

		Terminal (Growth								Delta EBIT	-margin					
Beta	WACC	2.75 %	3.00 %	3.25 %	3.50 %	3.75 %	4.00 %	4.25 %	Beta	WACC	-1.5 pp	-1.0 pp	-0.5 pp	+0.0 pp	+0.5 pp	+1.0 pp	+1.5 pp
1.56	11.1 %	3.29	3.35	3.40	3.46	3.52	3.59	3.66	1.56	11.1 %	3.16	3.26	3.36	3.46	3.56	3.66	3.76
1.47	10.6 %	3.54	3.61	3.67	3.74	3.82	3.90	3.99	1.47	10.6 %	3.42	3.53	3.64	3.74	3.85	3.96	4.07
1.42	10.3 %	3.68	3.75	3.82	3.90	3.99	4.08	4.18	1.42	10.3 %	3.57	3.68	3.79	3.90	4.02	4.13	4.24
1.38	10.1 %	3.83	3.91	3.99	4.07	4.17	4.27	4.38	1.38	10.1 %	3.72	3.84	3.96	4.07	4.19	4.31	4.43
1.33	9.8 %	3.99	4.07	4.16	4.26	4.37	4.48	4.60	1.33	9.8 %	3.90	4.02	4.14	4.26	4.38	4.50	4.63
1.28	9.6 %	4.16	4.26	4.36	4.46	4.58	4.71	4.85	1.28	9.6 %	4.08	4.21	4.34	4.46	4.59	4.72	4.84
1.19	9.1 %	4.55	4.67	4.79	4.92	5.07	5.24	5.41	1.19	9.1 %	4.51	4.65	4.79	4.92	5.06	5.20	5.34

• In 2013, one-third of the revenue was generated in the Trauma division and two-thirds in the Biomaterials division.

• This ratio will turn around in the medium term. As of 2020, Trauma is expected to generate almost 70% of revenue.

• 2013 EBIT was burdened by one-time effects. In 2015e, the Trauma division is expected to break even.

• The EBIT margin in perpetuity is assumed at 21%. With successful market penetration, higher margins are possible.

- Beta is relatively low owing to the good financial situation and the sector's resistance to cyclicality.

Sum of the parts

SotP aap Implantate

	Sa l 2014e	les 2015e	EV/ Sales 2014	EV/ Sales 2015	Trauma M&A Multiples	fair value 14	fair value 15	fair value 14 M&A
Trauma	11,00	17,9	4,49	3,97	4,67	49,4	71,0	51,3
Biomaterials	19,55	19,9	3,61	2,97	3,61	70,6	59,2	70,6
Other Assets								
Net Debt (without EMCM)						-13,0	-13,0	-13,0
Joint Venture aap Joints (at equity)						1,5	1,5	1,5
Fair Value						134,4	144,7	136,4
Number of shares						30,7	30,7	30,7
Fair Value per share						4,38	4,72	4,45

Quelle: Warburg Research, Bloomberg

ate	Buyer	Target company	EV/ (LTM) Sales	Transaction
2014	Wright Medical	OrthoPro	5,50	M&A
2014	Wright Medical	Solana Surgical	5,50	M&A
2013	Wright Medical	Biotech International	5,33	M&A
2013	LDR Holding		2,97	IPO
2013	Wright Medical	WG Healtcare	n.a	M&A
2012	Globus Medical		2,60	IPO
2012	Tornier	OrthoHelix	5,78	M&A
2011	Tonier		3,38	IPO
2011	Stryker	Memometal	5,40	M&A
2010	China Kanghui		5,55	IPO
		Mean	4,67	

Quelle: Warburg Research, Bloomberg





Valuation							
	2010	2011	2012	2013	2014e	2015e	2016e
Price / Book	0.8 x	0.6 x	0.6 x	0.9 x	1.4 x	1.3 x	1.2 x
Book value per share ex intangibles	0.28	0.34	0.37	1.11	1.10	1.20	1.33
EV / Sales	1.5 x	1.2 x	0.9 x	1.2 x	1.6 x	1.3 x	1.0 x
EV / EBITDA	12.8 x	8.7 x	4.8 x	6.6 x	17.0 x	9.1 x	6.9 x
EV / EBIT	61.3 x	30.8 x	10.7 x	n.a.	198.1 x	19.5 x	13.4 x
EV / EBIT adj.*	61.3 x	30.8 x	10.7 x	n.a.	198.1 x	19.5 x	13.4 x
P / FCF	n.a.	n.a.	9.6 x	n.a.	15.3 x	139.2 x	46.3 x
P/E	n.a.	96.9 x	12.5 x	n.a.	220.0 x	27.5 x	24.4 x
P / E adj.*	n.a.	96.9 x	12.5 x	n.a.	220.0 x	27.5 x	24.4 x
Dividend Yield	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	0.9 %	1.4 %
Free Cash Flow Yield Potential	7.5 %	2.6 %	11.0 %	8.6 %	0.1 %	4.7 %	6.1 %
*Adjustments made for: -							



Consolidated profit & loss

In EUR m	2010	2011	2012	2013	2014e	2015e	2016e
Sales	28.4	29.2	36.4	40.0	30.6	37.8	45.8
Change Sales yoy	-14.1 %	2.7 %	24.7 %	9.8 %	-23.6 %	23.9 %	21.1 %
Increase / decrease in inventory	0.8	0.8	0.2	-1.0	-0.3	0.0	0.0
Own work capitalised	3.3	3.0	2.7	2.0	1.5	1.1	1.4
Total Sales	32.6	33.0	39.3	41.0	31.8	39.0	47.2
Material Expenses	9.5	8.1	10.8	12.0	10.1	11.4	13.5
Gross profit	23.0	24.9	28.6	29.1	21.7	27.6	33.7
Gross profit margin	81.0 %	85.3 %	78.4 %	72.7 %	71.0 %	73.0 %	73.5 %
Personnel expenses	12.1	11.9	13.5	14.6	12.4	15.1	18.1
Other operating income	2.6	1.9	3.3	4.3	3.5	3.9	4.5
Other operating expenses	10.1	10.8	11.2	11.4	10.0	11.2	13.5
Unfrequent items	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBITDA	3.4	4.1	7.1	7.4	2.8	5.2	6.6
Margin	12.1 %	14.1 %	19.6 %	18.4 %	9.3 %	13.7 %	14.3 %
Depreciation of fixed assets	1.0	1.1	1.1	2.2	0.9	0.9	0.9
EBITA	2.4	3.1	6.0	5.2	1.9	4.3	5.6
Amortisation of intangible assets	1.7	1.9	2.8	7.3	1.7	1.9	2.3
Goodwill amortization	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBIT	0.7	1.2	3.2	-2.1	0.2	2.4	3.3
Margin	2.5 %	4.0 %	8.8 %	-5.3 %	0.8 %	6.4 %	7.3 %
EBIT adj.	0.7	1.2	3.2	-2.1	0.2	2.4	3.3
Interest income	0.0	0.1	0.0	0.0	0.3	0.3	0.3
Interest expenses	0.6	0.6	0.5	0.2	0.2	0.2	0.2
Other financial income (loss)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
EBT	0.2	0.6	2.7	-2.3	0.4	2.5	3.4
Margin	0.7 %	2.1 %	7.5 %	-5.7 %	1.3 %	6.7 %	7.5 %
Total taxes	0.1	0.2	0.3	0.2	0.2	0.2	0.6
Net income from continuing operations	0.1	0.4	2.4	-2.5	0.2	2.3	2.8
Income from discontinued operations (net of tax)	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income before minorities	0.0	0.4	2.4	-2.5	0.2	2.3	2.8
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Net income	0.0	0.4	2.4	-2.5	0.2	2.3	2.8
Margin	0.2 %	1.3 %	6.6 %	-6.1 %	0.6 %	6.1 %	6.2 %
Number of shares, average	27.8	29.6	30.7	30.7	30.7	30.7	30.7
EPS	0.00	0.01	0.08	-0.08	0.01	0.08	0.09
EPS adj.	0.00	0.01	0.08	-0.08	0.01	0.08	0.09
*Adjustments made for:							


Guidance: Guidance 2014: Revenue EUR 30-34m - EBITDA EUR 2-4.5m


Financial Ratios

	2010	2011	2012	2013	2014e	2015e	2016e
Total Operating Costs / Sales	102.4 %	98.9 %	88.5 %	84.2 %	94.7 %	89.3 %	88.7 %
Operating Leverage	5.7 x	23.1 x	7.1 x	n.a.	n.a.	37.3 x	1.8 x
EBITDA / Interest expenses	6.1 x	6.8 x	13.7 x	40.6 x	18.9 x	25.9 x	32.8 x
Tax rate (EBT)	72.6 %	36.1 %	11.5 %	-7.9 %	50.7 %	7.9 %	17.4 %
Dividend Payout Ratio	0.0 %	0.0 %	0.0 %	0.0 %	0.0 %	26.4 %	32.3 %
Sales per Employee	n.a.	109,793	137,932	n.a.	n.a.	n.a.	n.a.

2013 2014e 2015e 2016e







100.0 %

90.0 %

80.0 %

70.0 %

60.0 %

50.0 %

40.0 %


30.0 %

20.0 %

10.0 %

0.0 %

Performance per Share



COMMENT Published 06.11.2014

2012

- Gross profit margin - Total Operating Costs / Sales - EBIT margin

2010 2011

6




Consolidated balance sheet

In EUR m	2010	2011	2012	2013	2014e	2015e	2016e
Assets							
Goodwill and other intangible assets	37.0	38.2	39.4	14.5	14.8	14.9	14.6
thereof other intangible assets	6.1	5.5	5.1	0.9	1.2	1.3	1.0
thereof Goodwill	12.5	12.5	12.5	1.6	1.6	1.6	1.6
Property, plant and equipment	5.2	5.1	5.1	5.9	6.2	6.6	7.1
Financial assets	0.4	0.4	0.4	1.8	1.8	1.8	1.8
Other long-term assets	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Fixed assets	42.6	43.7	44.9	22.2	22.8	23.3	23.5
Inventories	12.7	14.0	13.9	9.4	6.8	7.6	8.3
Accounts receivable	6.2	5.5	4.2	7.0	4.2	5.2	6.3
Liquid assets	0.9	2.2	3.7	1.6	24.0	25.1	27.5
Other short-term assets	1.3	0.8	1.8	25.0	2.0	2.0	2.0
Current assets	21.1	22.5	23.7	43.0	37.0	39.9	44.1
Total Assets	63.6	66.2	68.6	65.2	59.8	63.2	67.6
Liabilities and shareholders' equity							
Subscribed capital	27.9	30.7	30.7	30.7	30.7	30.7	30.7
Capital reserve	40.0	40.4	18.6	18.8	18.8	18.8	18.8
Retained earnings	0.2	0.2	0.2	0.8	1.0	3.9	7.7
Other equity components	-23.4	-23.0	1.4	-1.7	-1.7	-1.7	-1.7
Shareholder's equity	44.7	48.4	50.9	48.5	48.7	51.6	55.4
Minority interest	0.1	0.0	0.0	0.0	0.0	0.0	0.0
Total equity	44.9	48.4	50.9	48.5	48.7	51.6	55.4
Provisions	0.2	0.2	0.2	0.3	0.3	0.3	0.3
thereof provisions for pensions and similar obligations	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial liabilites (total)	10.0	9.2	7.6	4.9	4.9	4.9	4.9
thereof short-term financial liabilities	5.5	5.5	4.5	2.6	2.6	2.6	2.6
Accounts payable	3.0	3.1	3.3	2.9	2.2	2.7	3.3
Other liabilities	5.6	5.2	6.7	8.7	3.7	3.7	3.7
Liabilities	18.8	17.8	17.7	16.7	11.1	11.6	12.2
Total liabilities and shareholders' equity	63.6	66.2	68.6	65.2	59.8	63.2	67.6

Financial Ratios

	2010	2011	2012	2013	2014e	2015e	2016e
Efficiency of Capital Employment							
Operating Assets Turnover	1.4 x	1.4 x	1.9 x	2.1 x	2.0 x	2.3 x	2.5 x
Capital Employed Turnover	0.5 x	0.5 x	0.7 x	0.8 x	1.0 x	1.2 x	1.4 x
ROA	0.1 %	0.9 %	5.4 %	-11.0 %	0.9 %	9.9 %	12.1 %
Return on Capital							
ROCE (NOPAT)	0.4 %	1.4 %	5.2 %	-4.3 %	0.3 %	7.3 %	8.6 %
ROE	0.1 %	0.8 %	4.9 %	-4.9 %	0.4 %	4.6 %	5.3 %
Adi. ROE	0.1 %	0.8 %	4.9 %	-4.9 %	0.4 %	4.6 %	5.3 %
Balance sheet quality							
Net Debt	9.1	7.1	3.9	3.3	-19.1	-20.2	-22.5
Net Financial Debt	9.1	7.1	3.9	3.3	-19.1	-20.2	-22.6
Net Gearing	20.3 %	14.7 %	7.7 %	6.9 %	-39.1 %	-39.0 %	-40.7 %
Net Fin. Debt / EBITDA	262.8 %	171.4 %	54.4 %	45.2 %	n.a.	n.a.	n.a.
Book Value / Share	1.6	1.6	1.7	1.6	1.6	1.7	1.8
Book value per share ex intangibles	0.3	0.3	0.4	1.1	1.1	1.2	1.3



Published 06.11.2014

Consolidated cash flow statement



In EUR m	2010	2011	2012	2013	2014e	2015e	2016e
Net income	0.0	0.4	2.4	-2.5	0.2	2.3	2.8
Depreciation of fixed assets	1.0	1.1	1.1	2.2	0.9	0.9	0.9
Amortisation of goodwill	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Amortisation of intangible assets	1.7	1.9	2.8	7.3	1.7	1.9	2.3
Increase/decrease in long-term provisions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Other non-cash income and expenses	0.2	0.2	-1.9	0.0	0.0	0.0	0.0
Cash Flow	3.0	3.5	4.5	7.0	2.8	5.1	6.1
Increase / decrease in inventory	-0.6	-0.5	1.4	-4.3	2.6	-0.8	-0.7
Increase / decrease in accounts receivable	0.0	0.0	0.0	0.0	2.8	-1.0	-1.1
Increase / decrease in accounts payable	0.3	0.2	1.3	0.8	-0.7	0.5	0.6
Increase / decrease in other working capital positions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Increase / decrease in working capital (total)	-0.3	-0.3	2.6	-3.5	4.8	-1.3	-1.2
Net cash provided by operating activities	2.7	3.2	7.1	3.5	7.6	3.8	4.9
Investments in intangible assets	-3.3	-3.1	-2.8	-5.7	-2.0	-2.0	-2.0
Investments in property, plant and equipment	-1.1	-0.9	-1.1	-1.1	-1.2	-1.3	-1.4
Payments for acquisitions	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Financial investments	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Income from asset disposals	0.0	0.3	0.0	3.5	18.0	0.0	0.0
Net cash provided by investing activities	-4.4	-3.7	-3.9	-3.3	14.8	-3.3	-3.4
Change in financial liabilities	0.3	-1.1	-1.4	-2.5	0.0	0.0	0.0
Dividends paid	0.0	0.0	0.0	0.0	0.0	0.6	0.9
Purchase of own shares	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Capital measures	0.0	3.0	0.0	0.0	0.0	0.0	0.0
Other	0.0	-0.1	-0.2	0.0	0.0	0.0	0.0
Net cash provided by financing activities	0.3	1.8	-1.6	-2.5	0.0	0.6	0.9
Change in liquid funds	-1.5	1.2	1.5	-2.3	22.4	1.1	2.4
Effects of exchange-rate changes on cash	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Cash and cash equivalent at end of period	0.9	2.2	3.7	1.4	24.0	25.1	27.5

Financial Ratios

	2010	2011	2012	2013	2014e	2015e	2016e
Cash Flow							
FCF	-1.8	-0.8	3.2	-3.3	4.4	0.5	1.5
Free Cash Flow / Sales	-6.3 %	-2.6 %	8.7 %	-8.2 %	14.4 %	1.3 %	3.2 %
Free Cash Flow Potential	3.3	0.9	3.8	4.2	0.0	2.2	2.7
Free Cash Flow / Sales	-6.3 %	-2.6 %	8.7 %	-8.2 %	14.4 %	1.3 %	3.2 %
Free Cash Flow / Net Profit	-3812.8 %	-197.2 %	132.3 %	133.6 %	2264.8 %	20.9 %	51.2 %
Interest Received / Avg. Cash	2.1 %	3.8 %	1.0 %	0.0 %	2.3 %	1.2 %	1.1 %
Interest Paid / Avg. Debt	5.7 %	6.3 %	6.2 %	2.9 %	3.1 %	4.1 %	4.1 %
Management of Funds							
Investment ratio	15.6 %	13.6 %	10.7 %	17.1 %	10.5 %	8.7 %	7.4 %
Maint. Capex / Sales	0.0 %	10.1 %	8.2 %	7.5 %	8.5 %	7.3 %	7.0 %
Capex / Dep	162.9 %	134.6 %	99.8 %	72.0 %	123.2 %	119.4 %	105.9 %
Avg. Working Capital / Sales	54.0 %	54.4 %	41.0 %	34.2 %	36.6 %	24.9 %	23.3 %
Trade Debtors / Trade Creditors	209.1 %	176.5 %	129.7 %	246.6 %	190.9 %	192.6 %	190.9 %
Inventory Turnover	0.8 x	0.6 x	0.8 x	1.3 x	1.5 x	1.5 x	1.6 x
Receivables collection period (days)	80	69	42	64	50	50	50
Payables payment period (days)	114	141	110	87	80	87	89
Cash conversion cycle (Days)	470	595	379	251	199	190	165





Free Cash Flow Generation

```
8
```

Working Capital



LEGAL DISCLAIMER

This research report was prepared by the Warburg Research GmbH, a subsidiary of the M.M.Warburg & CO (AG & Co.) KGaA and is passed on by the M.M.Warburg & CO (AG & Co.) KGaA. It contains selected information and does not purport to be complete. The report is based on publicly available information and data ("the information") believed to be accurate and complete. Warburg Research GmbH neither does examine the information to be accurate and complete, nor guarantees its accuracy and completeness. Possible errors or incompleteness of the information do not constitute grounds for liability of M.M.Warburg & CO (AG & Co.) KGaA or Warburg Research GmbH for damages of any kind whatsoever, and M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are not liable for indirect and/or direct and/or consequential damages. In particular, neither M.M.Warburg & CO (AG & Co.) KGaA nor Warburg Research GmbH are liable for the statements, plans or other details contained in these analyses concerning the examined companies, their affiliated companies, strategies, economic situations, market and competitive situations, regulatory environment, etc. Although due care has been taken in compiling this research report, it cannot be excluded that it is incomplete or contains errors. M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH, their shareholders and employees are not liable for the accuracy and completeness of the statements, estimations and the conclusions derived from the information contained in this document. Provided a research report is being transmitted in connection with an existing contractual relationship, i.e. financial advisory or similar services, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH shall be restricted to gross negligence and wilful misconduct. In case of failure in essential tasks, M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are liable for normal negligence. In any case, the liability of M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH is limited to typical, expectable damages. This research report does not constitute an offer or a solicitation of an offer for the purchase or sale of any security. Partners, directors or employees of M.M.Warburg & CO (AG & Co.) KGaA, Warburg Research GmbH or affiliated companies may serve in a position of responsibility, i.e. on the board of directors of companies mentioned in the report. Opinions expressed in this report are subject to change without notice. All rights reserved.

COPYRIGHT NOTICE

This work including all its parts is protected by copyright. Any use beyond the limits provided by copyright law without permission is prohibited and punishable. This applies, in particular, to reproductions, translations, microfilming, and storage and processing on electronic media of the entire content or parts thereof.

DISCLOSURE ACCORDING TO §34B (1) OF THE GERMAN SECURITIES TRADING ACT (WHPG) AND THE ORDINANCE ON THE ANALYSIS OF FINANCIAL INSTRUMENTS (FINANV)

The valuation underlying the investment recommendation for the company analysed here is based on generally accepted and widely used methods of fundamental analysis, such as e.g. DCF Model, Free Cash Flow Potential, Peer Group Comparison or Sum of the Parts Model. The result of this fundamental valuation is modified to take into consideration the analyst's assessment as regards the expected development of investor sentiment and its impact on the share price.

Independent of the applied valuation methods, there is the risk that the price target will not be met, for instance because of unforeseen changes in demand for the company's products, changes in management, technology, economic development, interest rate development, operating and/or material costs, competitive pressure, supervisory law, exchange rate, tax rate etc. For investments in foreign markets and instruments there are further risks, generally based on exchange rate changes or changes in political and social conditions.

This commentary reflects the opinion of the relevant author at the point in time of its compilation. A change in the fundamental factors underlying the valuation can mean that the valuation is subsequently no longer accurate. Whether, or in what time frame, an update of this commentary follows is not determined in advance.

In accordance with § 5 (4) of the Ordinance on the Analysis of Financial Instruments (FinAnV) Warburg Research GmbH has implemented additional internal and organisational arrangements to prevent or to deal with conflicts of interest. Among these are the spatial separation of Warburg Research GmbH from M.M.Warburg & CO (AG & Co.) KGaA and the creation of areas of confidentiality. This prevents the exchange of information, which could form the basis of conflicts of interest for Warburg Research in terms of the analysed issuers or their financial instruments.

The analysts of Warburg Research GmbH do not receive a gratuity – directly or indirectly – from the investment banking activities of M.M.Warburg & CO (AG & Co.) KGaA or of any company within the Warburg Group.

All prices of financial instruments given in this financial analysis are the closing prices on the last stock-market trading day before the publication date stated, unless another point in time is explicitly stated.

M.M.Warburg & CO (AG & Co.) KGaA and Warburg Research GmbH are subject to the supervision of the Federal Financial Supervisory Authority, BaFin.

SOURCES

All data and consensus estimates have been obtained from FactSet except where stated otherwise.

Reference in accordance with section 34b of the German Securities Trading Act (WpHG) and the Ordiance on the Analysis of Financial Instruments (FinAnV) regarding possible conflicts of interest with the analysed company:

-1-	The company preparing the analysis or any of its affiliated companies hold over 5% of shares in the analysed company's equity capital.
-2-	Within the last twelve months, the company preparing the analysis or any of its affiliated companies have participated in the management of a consortium for the public offering of financial securities, which are (or the issuer of which) is the subject of the analysis.
-3-	The company preparing the analysis or any of its affiliated companies manage the securities of the analysed company on the grounds of an existing contract.
-4-	On the grounds of an existing contract, the company preparing the analysis or any of its affiliated companies, have managed investment banking services for the analysed company within the last twelve months, out of which a service or the promise of a has service emerged.
-5-	The company preparing the analysis and the analysed company came to an agreement regarding the preparation of the financial analysis.
-6-	The company preparing the analysis or any of its affiliated companies regularly trade in shares or derivatives of the analysed company.
-7-	The company preparing the analysis as well as its affiliated companies and employees have other important interests in relation to the analysed company, such as, for example, the exercising of mandates at analysed companies.

Company	Disclosure	Link to the historical price targets and rating changes (last 12 months)
aap Implantate	5	http://www.mmwarburg.com/disclaimer/disclaimer_en/DE0005066609.htm

INVESTMENT RECOMMENDATION

Investment recommendation: expected direction of the share price development of the financial instrument up to the given <u>price target</u> in the opinion of the analyst who covers this financial instrument.

-B-	Buy:	The price of the analysed financial instrument is expected to rise over the next 12 months.
-H-	Hold:	The price of the analysed financial instrument is expected to remain mostly flat over the next 12 months.
-S-	Sell:	The price of the analysed financial instrument is expected to fall over the next 12 months.
"_"	Rating suspended:	The available information currently does not permit an evaluation of the company.

WARBURG RESEARCH GMBH - RESEARCH UNIVERSE BY RATING


Rating	Number of stocks	% of Universe
Buy	112	60
Hold	64	34
Sell	7	4
Rating suspended	5	3
Total	188	100

WARBURG RESEARCH GMBH - ANALYSED RESEARCH UNIVERSE BY RATING ...

... Looking only at companies for which a disclosure according to § 34b of the Germany Securities Trading Act and the FinAnV has to be made.

Rating	Number of stocks	% of Universe
Buy	94	63
Hold	48	32
Sell	4	3
Rating suspended	4	3
Total	150	100

PRICE AND RATING HISTORY AAP IMPLANTATE AS OF 06.11.2014



The chart has markings if Warburg Research GmbH changed its rating in the last 12 months. Every marking represents the date and closing price on the day of the rating change.

EQUITIES

Roland Rapelius Head of Equities

RESEARCH

Henner Rüschmeier Head of Research

Christian Cohrs Engineering, Logistics

Felix Ellmann Software, IT

Jörg Philipp Frey Retail, Consumer Goods

Harald Hof Medtech

Ulrich Huwald Health Care, Pharma

Thilo Kleibauer Retail, Consumer Goods

Eggert Kuls Engineering

Frank Laser Construction, Industrials

Andreas Pläsier Banks, Financial Services

INSTITUTIONAL EQUITY SALES

Holger Nass Head of Equity Sales, USA Klaus Schilling

Dep. Head of Equity Sales, GER

Christian Alisch Scandinavia, Spain

Tim Beckmann United Kingdom

Matthias Fritsch United Kingdom

Marie-Therese Grübner France

SALES TRADING

Oliver Merckel Head of Sales Trading

Thekla Struve Dep. Head of Sales Trading

Gudrun Bolsen Sales Trading

Michael Ilgenstein Sales Trading

MACRO RESEARCH

Carsten Klude Macro Research Matthias Thiel

Macro Research

+49 40 309537-270 hrueschmeier@warburg-research.com

+49 40 309537-220

+49 40 309537-175 ccohrs@warburg-research.com

rrapelius@warburg-research.com

+49 40 309537-120 fellmann@warburg-research.com

> +49 40 309537-258 jfrey@warburg-research.com

+49 40 309537-125 hhof@warburg-research.com

+49 40 309537-255 uhuwald@warburg-research.com

+49 40 309537-257 tkleibauer@warburg-research.com

> +49 40 309537-256 ekuls@warburg-research.com

+49 40 309537-235 flaser@warburg-research.com

+49 40 309537-246 aplaesier@warburg-research.com

+49 40 3282-2669 hnass@mmwarburg.com

+49 40 3282-2664 kschilling@mmwarburg.com

+49 40 3282-2667 calisch@mmwarburg.com

+49 40 3282-2665 tbeckmann@mmwarburg.com

+49 40 3282-2696 mfritsch@mmwarburg.com

+49 40 3282-2630 mgruebner@mmwarburg.com

+49 40 3282-2634 omerckel@mmwarburg.com

+49 40 3282-2668 tstruve@mmwarburg.com

+49 40 3282-2679 gbolsen@mmwarburg.com

+49 40 3282-2700 milgenstein@mmwarburg.com

> +49 40 3282-2572 cklude@mmwarburg.com +49 40 3282-2401 mthiel@mmwarburg.com

Malte Räther Technology, Telco, Internet

Jochen Reichert Telco, Internet, Media

Christopher Rodler

Utilities

Malte Schaumann Technology

Oliver Schwarz Chemicals, Agriculture

Marc-René Tonn Automobiles, Car Suppliers

Björn Voss Steel, Car Suppliers

Andreas Wolf Software, IT

Stephan Wulf Utilities

Ömer Güven USA, Germany

Michael Kriszun United Kingdom

Marc Niemann Germany

Sanjay Oberoi United Kingdom

Bastian Quast

Sales Trading

Sales Trading

Jan Walter

Sales Trading

Juliane Willenbruch

Dr. Christian Jasperneite

Roadshow/Marketing

Investment Strategy

Jörg Treptow

Philipp Stumpfegger Australia, United Kingdom +49 40 309537-185 mraether@warburg-research.com

+49 40 309537-130 jreichert@warburg-research.com

+49 40 309537-290 crodler@warburg-research.com

+49 40 309537-170 mschaumann@warburg-research.com

+49 40 309537-250 oschwarz@warburg-research.com

+49 40 309537-259 mtonn@warburg-research.com

+49 40 309537-254 bvoss@warburg-research.com

+49 40 309537-140 awolf@warburg-research.com

+49 40 309537-150 swulf@warburg-research.com

+49 40 3282-2633 ogueven@mmwarburg.com

+49 40 3282-2695 mkriszun@mmwarburg.com

+49 40 3282-2660 mniemann@mmwarburg.com

+49 69 5050-7410 soberoi@mmwarburg.com

+49 40 3282-2635 pstumpfegger@mmwarburg.com

> +49 40 3282-2701 bquast@mmwarburg.com +49 40 3262-2658 jtreptow@mmwarburg.com +49 40 3262-2662

jwalter@mmwarburg.com

+49 40 3282-2694 jwillenbruch@mmwarburg.com

+49 40 3282-2439 cjasperneite@mmwarburg.com

Our research can be found under:

Warburg Research	research.mmwarburg.com/en/index.html	Thomson	www.thomson.com
Bloomberg	MMWA GO	Reuters	www.knowledge.reuters.com
FactSet	www.factset.com	Capital IQ	www.capitaliq.com
For access please co	ontact:		
Andrea Schaper Sales Assistance	+49 40 3282-2632 aschaper@mmwarburg.com	Kerstin Muthig Sales Assistance	+49 40 3282-2703 kmuthig@mmwarburg.com

WARBURG RESEARCH